Notify me when Bain Capital Life Sciences Fund, L.P. files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ANNX | Annexon, Inc. | Common Stock, par value $0.001 per share | 4.9% | $9,973,231 | 5,249,069 | BCLS I Investco, LP | 31 Dec 2024 | ||
| PHVS | Pharvaris N.V. | Ordinary Shares, Euro 0.12 par value per share | 2.5% | $41,020,425 | -$5,670,300 | 1,640,817 | -12% | Bain Capital Life Sciences Fund, L.P. | 31 Dec 2025 |
| XFOR | X4 PHARMACEUTICALS, INC. | Common Stock, par value $0.001 per share | 0% | $0 | -$9,478,327 | 0 | -100% | Bain Capital Life Sciences Fund, L.P. | 31 Dec 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|